At GoBroad, we understand the complexities of leukemia, a type of blood cancer that affects patients of all ages. Our mission is to provide advanced and effective leukemia cancer treatment options, ensuring that each patient receives comprehensive care tailored to their unique needs. Our innovative therapies include single-target CAR-T therapy, sequential dual-target CAR-T cell therapy, hematologic stem cell transplantation (HSCT), and combined treatment approaches.

Advanced CAR-T Therapies

One of the most promising advancements in leukemia cancer treatment is CAR-T therapy. At GoBroad, we offer single-target CAR-T therapy that specifically targets antigens such as CD19, CD20, CD22, CD7, CD5, GPRC5D, and CLL1. This therapy harnesses the power of the patient’s own immune cells, transforming them into cancer-fighting machines. By targeting specific proteins on leukemia cells, we improve the chances of remission and minimize side effects compared to traditional treatments.

In addition to single-target therapy, we also provide sequential dual-target CAR-T cell therapy for patients with refractory or relapsed acute leukemia. This innovative approach allows us to target multiple antigens simultaneously, significantly enhancing the treatment’s effectiveness. This therapy is crucial for patients who have not responded to other forms of leukemia cancer treatment.

Hematologic Stem Cell Transplantation

Another cornerstone of our leukemia cancer treatment offerings is hematologic stem cell transplantation (HSCT). This procedure is suitable for patients ranging from 1 month to 74 years old who have refractory or relapsed acute leukemia. At GoBroad, we have successfully completed thousands of HSCT cases, applying innovative methods that ensure high success rates and low complication rates. Our experienced team is dedicated to providing personalized care throughout the transplantation process, making it a viable option for many patients.

Combined Treatment Approaches

At GoBroad, we believe in a holistic approach to leukemia cancer treatment. Our combined treatment options integrate CAR-T therapy with chemotherapy, targeted therapy, or allogeneic hematopoietic stem cell transplantation (allo-HSCT). This multifaceted approach is designed for patients with challenging cases of refractory or relapsed acute leukemia, maximizing the potential for recovery. By leveraging various treatment modalities, we aim to improve outcomes and enhance the quality of life for our patients.

Conclusion

In summary, GoBroad is committed to delivering cutting-edge leukemia cancer treatment through advanced therapies like CAR-T and HSCT, as well as innovative combined treatment strategies. Our goal is to provide comprehensive care that meets the specific needs of each patient, regardless of their age or stage of the disease. With a focus on personalized treatment plans and a dedication to patient well-being, GoBroad is at the forefront of leukemia cancer treatment. If you or a loved one is facing a leukemia diagnosis, we invite you to explore our advanced treatment options and join us in the fight against cancer. Together, we can navigate this journey toward recovery.